Effect of cardioplegic and organ preservation solutions and their components on coronary endothelium-derived relaxing factors.
Cardioplegic (and organ preservation) solutions were initially designed to protect the myocardium (cardiac myocytes) during cardiac operation (and heart transplantation). Because of differences between cardiac myocytes and vascular (endothelial and smooth muscle) cells in structure and function, the solutions may have an adverse effect on coronary vascular cells. However, such effect is often complicated by many other factors such as ischemia-reperfusion injury, temperature, and perfusion pressure or duration. To evaluate the effect of a solution on the coronary endothelial function, a number of points should be taken into consideration. First, the overall effect on endothelium should be identified. Second, the effect of the solution on the individual endothelium-derived relaxing factors (nitric oxide, prostacyclin, and endothelium-derived hyperpolarizing factor) must be distinguished. Third, the effect of each major component of the solution should be investigated. Lastly, the effect of a variety of new additives in the solution may be studied. Based on available literature these issues are reviewed to provide information for further development of cardioplegic or organ preservation solutions.
Yang
Qin
Q
Department of Surgery, Oregon Health & Science University, Portland, Oregon, USA.
He
Guo-Wei
GW
D002314:Cardioplegic Solutions / Q000494:pharmacology*; D003331:Coronary Vessels / Q000187:drug effects*; D004730:Endothelium, Vascular / Q000187:drug effects*; D045462:Endothelium-Dependent Relaxing Factors / Q000378:metabolism*; D011464:Epoprostenol / Q000096:biosynthesis; D006801:Humans; D009569:Nitric Oxide / Q000096:biosynthesis; D019188:Organ Preservation Solutions / Q000494:pharmacology*
D002314:Cardioplegic Solutions; D045462:Endothelium-Dependent Relaxing Factors; D019188:Organ Preservation Solutions; D009569:Nitric Oxide; D011464:Epoprostenol